Portfoliotracker

Cipher Pharmaceuticals Inc.

CPH.TO · TORONTO · Healthcare Drug Manufacturers - Specialty & Generic 90/100 A

13,40 CAD
▼ −0,77 (−5,43 %)
Closed delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 11:40
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score90 / 100 Market cap342 mil. CAD P/E8,8 Forward P/E11,8 P/S6,9 P/B1,7 EV/EBITDA11,0 Dividend yield– FCF yield– EPS1,53 CAD Net margin69,5 % Return on equity26,4 % Beta– Debt / equity0,00
52-week range 12,76 to 20,56
3-month average volume0,0 M

We do not have financial statements yet

The company reports in USD, while the price is quoted in CAD. We do not convert statements between currencies yet, because the multiples (P/E, P/S and others) would come out wrong, so we do not show them here. You can see the price and its history above.

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company's licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C. Its pipeline products include piclidenoson CF-101, a novel chemical entity for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.

Country
Canada
Data since
7. 5. 2004

Explore further

Similar companies VHI.TOGUD.TOFTG.TODRX.TO

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account